Header Logo

Connection

CHARLES WYKOFF to Cost-Benefit Analysis

Back to Details
This is a "connection" page, showing publications CHARLES WYKOFF has written about Cost-Benefit Analysis.
CHARLES WYKOFF
Connection Strength
0.147
Cost-Benefit Analysis
  1. Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis. J Manag Care Spec Pharm. 2021 Jun; 27(6):743-752.
    View in: PubMed
    Score: 0.147
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.